Montelukast tablets oral treatment

PreclinicalSmall molecule

Montelukast tablets oral treatment is one of 3 small molecule programs targeting SARS CoV 2 Infection. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

SARS Cov 2 InfectionNot yet recruiting

SARS Cov 2 InfectionPreclinical

Not yet recruiting

Competition

Competitive Landscape

3 competitors in SARS Cov 2 Infection

#DrugCompanyPhaseTrials

Ibuzatrelvir

Pfizer

Phase 3

1 2

Montelukast tablets oral treatment

HHuashan Hospital

Preclinical

1 3

Stool Simple

HHospices Civils de Lyon

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

N/ANot yet recruiting

SARS Cov 2 Infection

NCT06597682

Clinical

Trials by Indication[1]

SARS CoV 2 Infection1 trial

Evaluating Immunomodulatory Interventions in Post-Acute Sequelae of SARS-CoV-2 InfEction

Not yet recruiting·HHuashan Hospital·N/A·NCT06597682·632 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Montelukast tablets oral treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Montelukast tablets oral treatment compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Montelukast tablets oral treatment. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Huashan Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: HHuashan Hospital

Montelukast tablets oral treatment

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

SARS CoV 2 Infection1 trial

References

Drug Info

Quick Facts

Related News